In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, AbbVie invests $380 million to expand API manufacturing capacity while Bora Pharmaceuticals and GSK enter a five-year manufacturing agreement, Novo Nordisk announces significant price reductions for its leading GLP-1 therapies, and Astellas enters a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting cancer treatments.
AbbVie is investing $380 million to expand its active pharmaceutical ingredient manufacturing capacity, reinforcing the company’s commitment to strengthening supply chain resilience and supporting long-term portfolio growth. In related manufacturing developments, Bora Pharmaceuticals and GSK have entered a five-year manufacturing agreement designed to enhance production capabilities and ensure steady supply. Together, these moves highlight continued industry focus on strategic production partnerships and domestic capacity expansion amid evolving global trade and regulatory pressures.
Novo Nordisk has announced significant price reductions for several of its popular GLP-1 medications, a notable shift in the highly competitive diabetes and obesity market. The move comes as pricing scrutiny intensifies and competition within the GLP-1 category accelerates. Lower list prices may improve patient access while also reshaping competitive dynamics among major players in the rapidly expanding cardiometabolic space.
Finally, Astellas has entered a billion-dollar global collaboration with Vir Biotechnology to advance PSMA-targeting therapies in oncology. The partnership combines Vir’s protein engineering capabilities with Astellas’ global development and commercialization expertise, aiming to accelerate next-generation treatments in prostate cancer. The deal underscores continued big pharma appetite for innovative oncology platforms and strategic external partnerships.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
